

REPROCELL AND FOX CHASE CANCER CENTER PARTNER TO OPEN MULTI-SITE BIOSAMPLE REPOSITORY IN INDIA

JOINT VENTURE PROVIDES QUALITY SOURCE OF CLINICALLY ANNOTATED TISSUE SPECIMENS FROM VAST INDIAN POPULATION

Location: REPROCELL USA Inc. (Beltsville, MD)
Business Unit: REPROCELL Discovery
Date: May 24, 2017

Announcement (Marketwired) — REPROCELL and Fox Chase Cancer Center today announced a joint venture to open a multi-site bio-sample repository facility in India. Initial operations are underway in Delhi with plans to expand to Hyderabad in the fourth quarter.

“The research community’s demand for access to clinical-grade bio-specimens from India has gone largely unmet. Through our partnership with Fox Chase, we plan to change that,” said Rama Modali, CEO of REPROCELL USA. “We’ve begun growing our inventory of bio-samples in India using the same rigorous quality-assurance standards we employ at our facilities in the US, including the collection and storage of all associated annotated clinical and genetic information and bioinformatics data analytics.”

The joint venture’s India facilities add approximately 3,000 new bio-samples monthly. Collected specimens are supported by annotations that include medical history, mutation data and detailed records of treatment protocols as well as outcomes.

“This alliance further augments our already impressive and extensive combined bio-sample inventory, helping us better serve the global cancer research community,” said Richard I. Fisher, MD, president & CEO of Fox Chase Cancer Center.

As a leading provider of biomaterials, REPROCELL is deeply engaged with cancer and other disease research being conducted by pharma, biotech and leading academic research institutions worldwide.

About Fox Chase Cancer Center — The Hospital of Fox Chase Cancer Center and its affiliates (collectively “Fox Chase Cancer Center”), a member of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes.

Fox Chase physicians are also routinely recognized in national rankings, and the Center's nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).

About REPROCELL — Headquartered in Yokohama (Japan), REPROCELL is an integrated research and medical company. Serving the global market, the REPROCELL Discovery business unit is focused on providing drug discovery services and products including human tissues and cutting-edge iPS stem cell technologies. Leveraging this history and strength, the REPROCELL Medical business unit (*formed 2017*) is pioneering stem cell-based applications for regenerative medicine therapies and human diagnostics. REPROCELL (<https://reprocell.com>) is a public company traded on the JASDAQ market. For more information on this press release contact your regional REPROCELL office (phone numbers and e-mails provided on the website listed above).

Follow us on social media:

Facebook: <https://www.facebook.com/REPROCELLglobal>
Twitter: <https://twitter.com/REPROCELLglobal>
LinkedIn: <https://www.linkedin.com/company/reprocell/>